GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Henry Schein Inc (NAS:HSIC) » Definitions » 3-Year Sharpe Ratio

HSIC (Henry Schein) 3-Year Sharpe Ratio : -0.08 (As of Jul. 19, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Henry Schein 3-Year Sharpe Ratio?

The 3-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past three years. As of today (2025-07-19), Henry Schein's 3-Year Sharpe Ratio is -0.08.


Competitive Comparison of Henry Schein's 3-Year Sharpe Ratio

For the Medical Distribution subindustry, Henry Schein's 3-Year Sharpe Ratio, along with its competitors' market caps and 3-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Henry Schein's 3-Year Sharpe Ratio Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, Henry Schein's 3-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Henry Schein's 3-Year Sharpe Ratio falls into.


;
;

Henry Schein 3-Year Sharpe Ratio Calculation

The 3-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset in the last three years. A stock / portfolio's 3-Year Sharpe Ratio can be calculated by dividing the difference between the three-year average monthly returns of the investment and the risk-free rate, by the standard deviation of the investment returns over the past three years.


Henry Schein  (NAS:HSIC) 3-Year Sharpe Ratio Explanation

The 3-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past three years. It is calculated as the annualized result of the average three-year monthly excess returns divided by its standard deviation in the three-year period. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Henry Schein 3-Year Sharpe Ratio Related Terms

Thank you for viewing the detailed overview of Henry Schein's 3-Year Sharpe Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Henry Schein Business Description

Address
135 Duryea Road, Melville, NY, USA, 11747
Henry Schein Inc is a solutions company for healthcare professionals powered by a network of people and technology. The company is a provider of healthcare products and services to office-based dental and medical practitioners, as well as alternate sites of care. The company's reportable segments are global Distribution and Value-Added Services; global Specialty Products; and global Technology. It generates the majority of its revenue from the global Distribution and Value-Added Services segment which includes distribution to the global dental and medical markets of national brand and corporate brand merchandise, as well as equipment and related technical services.
Executives
Bradford C Connett officer: CEO, NA Distribution Group C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Philip A Laskawy director 9 CREAMER HILL ROAD, GREENWICH CT 06831
Kurt P Kuehn director C/O HENRY SCHEIN, INC, 135 DURYEA ROAD, MELVILLE NY 11747
Michael S Ettinger officer: SVP, General Counsel, Sec. C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Lorelei Mcglynn officer: SVP, Global HR & Fin. Oper. C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Mark E Mlotek director, officer: SVP, Corp Bus Dev Group C/O HENRY SCHEIN INC, 135 DURYEA RD, MELVILLE NY 11747
Walter Siegel officer: Senior VP & General Counsel C/O HENRY SCHEIN, INC, 135 DURYEA RD, MELVILLE NY 11747
James P Breslawski director, officer: Executive Vice President C/O HENRY SCHEIN INC, 135 DURYEA RD, MELVILLE NY 11747
Stanley M Bergman director, officer: President and CEO C/O HENRY SCHEIN INC, 135 DURYEA ROAD, MELVILLE NY 11747
Brous David B Jr officer: CEO, Strategic Business Group C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Gerald A Benjamin director, officer: Executive V.P and CAO C/O HENRY SCHEIN, INC, 135 DURYEA RD, MELVILLE NY 11747
Ronald N. South officer: SVP & Chief Financial Officer C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Scott Philip Serota director C/O HENRY SCHEIN, INC., 135 DURYEA ROAD, MELVILLE NY 11747
Reed Vaughn Tuckson director C/O UNITEDHEALTH GROUP INCORPORATED, 9900 BREN ROAD EAST, MINNETONKA MN 55123
Steven Paladino director, officer: Executive V.P. and CFO C/O HENRY SCHEIN INC, 135 DURYEA RD, MELVILLE NY 11747